| Literature DB >> 31756937 |
Rodica Mărgăoan1, Mirela Stranț2, Alina Varadi2, Erkan Topal3, Banu Yücel4, Mihaiela Cornea-Cipcigan5, Maria G Campos6,7, Dan C Vodnar8.
Abstract
Bee products were historically used as a therapheutic approach and in food consumption, while more recent data include important details that could validate them as food supplements due to their bioproperties, which support their future use as medicines. In this review data, data collected from bee pollen (BP) and bee bread (BB) essays will be discussed and detailed for their nutritional and health protective properties as functional foods. Dietary antioxidants intake derived from BP and BB have been associated with the prevention and clinical treatment of multiple diseases. The beneficial effects of BP and BB on health result from the presence of multiple polyphenols which possess anti-inflammatory properties, phytosterols and fatty acids, which play anticancerogenic roles, as well as polysaccharides, which stimulate immunological activity. From the main bioactivity studies with BP and BB, in vitro studies and animal experiments, the stimulation of apoptosis and the inhibition of cell proliferation in multiple cell lines could be one of the major therapeutic adjuvant effects to be explored in reducing tumor growth. Tables summarizing the main data available in this field and information about other bio-effects of BP and BB, which support the conclusions, are provided. Additionally, a discussion about the research gaps will be presented to help further experiments that complete the tree main World Health Organization (WHO) Directives of Efficiency, Safety and Quality Control for these products.Entities:
Keywords: antioxidant activity; bee bread; bee pollen; cancer; diseases; health; natural product
Year: 2019 PMID: 31756937 PMCID: PMC6943659 DOI: 10.3390/antiox8120568
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Therapeutic properties of different pollen types in folk medicine (after [13]).
| Properties | Bee Pollen Type |
|---|---|
| Antibiotic | |
| Anti-atherogenic | |
| Anti-anemia | |
| Antitussives | |
| Diuretic | |
| Digestive | |
| Cardioprotective | |
| Hepatoprotective | |
| Kidney function | |
| Immunomodulating | |
| Ulcer healing |
Figure 1Examples of Flavonoid structures found in bee pollen (BP) and bee bread (BB), from [53] (with permission of the authors). Structure (a): Kaempferol-3-O-[rhamnosyl (1-2) glucoside] (RT (retention time) = 33.2; λmax = 265, 290 sh, 320 sh, 350 nm); (b): Quercetin-3-O-[glucosyl (1-2) glucoside] (RT = 30.6; λmax = 255, 266 sh, 294 sh, 355 nm).
Current therapeutic properties of different bee pollen and bee bread type.
| Functional Properties | BP and BB Type | Extract Type or Concentration | Bioactivity | References |
|---|---|---|---|---|
| Anti microbial | 10 g of | Inhibition zone diameter: A1 (9–21 mm) against | [ | |
| N/S | Marked antibiotic activity against | [ | ||
| 10 g of pollen extracted in 99.9% and 70% ( | MEh and MEl: 2.33–3.00 mm against | [ | ||
| 10 g of pollen extracted in 99.9% and 70% ( | MEh and MEl: 2.33–3.67 mm against | [ | ||
| 10 g of pollen extracted in 99.9% and 70% ( | MEh and MEl: 0.67–2.67 mm against | [ | ||
| BB—predominant | Hydro methanolic BB extract of 20 mg/mL in water | MIC: 0.04 mg/mL against | [ | |
| BB—predominant | Hydro methanolic BB extract of 20 mg/mL in water | MIC: 0.35 mg/mL against | [ | |
| Antioxidant | Selected monofloral species | 2 g of BP extracted in 15 mL methanol | DPPH value ranging between: 0.135–2.814 mmol Trolox g–1, in | [ |
| BB—predominant | 1 g of BB stirred with 30 mL methanol/water (80:20 | Total antioxidant capacity (mg AA/g extract) 143 ± 22 | [ | |
| Selected monofloral species | 0.25 mL BP in 80% methanol | Total antioxidant activity (%): 6.8–86.4 in | [ | |
| 0.5 g of pollen extracted with 10 mL of 80% methanol and 50% ethanol | Methanolic extract: TPC: 816 mg/kg GAE of DW; TFC: 843 mg/kg QE DW; | [ | ||
| Anti-carcinogenic | 1.95 g pollen fraction (chloroform extract) with 12.5, 25, 50 and 100 μg/mL of pollen extract administered for 24 h | Citotoxicity in MCF-7, Hela, BEL-7402, BCG-823, KB, A549 and HO8910 cells with 100 μg/mL extract | [ | |
| 1 g bee pollen mixed with 9 mL 70% ethanol with final concentrations of: 1 mg/mL, 10 mg/mL and 100 mg/mL at 24 h until harvest (72 h) | [ | |||
| Anti-inflammatory | Three times extracted pollen with 70% | Significant effect in formalin test of mice with pollen (100 and 200 mg/kg) at the first (0–5 min) and second phase (15–30 min); | [ | |
| 200 g of BP extracted with water or 95% ethanol; | ↓ inhibition of carrageenan-induced edema at 300 mg/kg water PB; ↑ inhibition of carrageenan-induced edema at 100 and 300 mg/kg (48.4% and 43.5%) | [ | ||
| Anti-osteoporosis | 5 g of BP in 20 mL distilled water, with concentrations of 10, 100, 1000 µg/mL | ↑ calcium content (mg/g dry bone) on VD3-induced decrease, in the femoral-diaphyseal and metaphyseal tissues by BP dose increase | [ | |
| 5 g of BP in 20 mL distilled water, with concentrations of 10, 50 and 100 µg/mL BP extracts fractioned to less than MW 1000 (A), from MW 1000 to MW 10,000 (B) and greater than MW 10,000 (C) | ↑ calcium content (mg/g dry bone) in rat femoral-diaphyseal tissues in the presence of 50 μg/mL BP extract (< MW 1000) and moderately higher in the presence of 100 μg/mL in all BP fractioned extracts | [ | ||
| 5 g of BP in 20 mL distilled water (oral administration) | ↑ calcium content (mg/g dry bone) in the femoral-diaphyseal and metaphyseal tissues by oral administration of BP water extracts (5 and 10 mg/mL/100 g body weight) | [ | ||
| 5 g of BP in 20 mL distilled water (oral administration) | ↑ calcium content (mg/g dry bone) in the femoral-diaphyseal or metaphyseal tissues in the presence of water-solubilized extract (100 µg/mL), best results in | [ | ||
| 5 g of BP in 20 mL distilled water, with final concentrations of | ↑ calcium content in the femoral-diaphyseal (5, 10 mg/100 g) or metaphyseal (5, 10 or 20 mg/100 g) tissues in the presence of water-solubilized extract (5, 10 or 20 mg/100 g) in STZ-diabetic rats | [ | ||
| Hepatoprotective | 30 g of BP in 100 mL distilled water, with orally administered concentrations of: G1 (control): 1mL of distillated water + 1 mL SO; | ↓ plasma and tissue (liver, kidney, brain, heart) MDA (nmol/mL-nmol/mg-prot) levels in the WSBP-treated group (G2) and propoxur + WSBP (G4) compared to propoxour treated ones (G3); | [ | |
| 1 g of BP with 10 mL methanol, with orally administered concentrations: G1 (control): 0.9% NaCl (i.p.); G2 (control): 0.8 mL/kg OO (i.p.); G3 (control) 0.8 mL/kg Ethanol (i.p.); G4 (CCI4) 0.8 mL/kg CCI4 in OO; G5 (Silibinin) 0.8 mL/kg CCI4 in OO + Silibinin (50 mg/kg/day) gavage; G6 (low BP) 0,8 mL/kg CCI4 in OO (i.p.) + BP (200 mg/kg/day) gavage; G7 (high BP) 0,8 mL/kg CCI4 in OO (i.p.) + BP (400 mg/kg/day) gavage | Protective effect of hepatocytes from oxidative stress | [ |
Note: AA—allyl alcohol; ABTS—2,2’-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid; AI—apoptois index, ALT—alanine aminotransferase; AST—aspartate aminotransferase; ATCC—American Type Culture Collection; BB—bee bread; BP—bee collected pollen; CCI4—carbon tetrachloride; CCM—Czech Collection of Microorganisms; COX-1—cyclooxygenase-1, COX-2—cyclooxygenase-2; DPPH—1,1-diphenyl-2-picrylhydrazyl; DW—dry weight,; Eh—96% ethanol extract; El—70% ethanol extract; GAE—gallic acid equivalents, HRSA—hydroxyl radical-scavenging activity; i.p.—intraperitoneal, MDA—malondialdehyde; MIC—minimal inhibition concentration, MBC—minimal bactericidal concentration, Meh—99.9% methanol extract and Mel—70% methanol extract; MNCs—multinucleated cells; MRSA—methicillin resistant Staphylococcus aureus, OO—olive oil; PGE2—prostaglandin E2; PTH—synthetic human parathyroid hormone; SOD—superoxide dismutase; TEAC—Trolox equivalent antioxidant capacity; TFC—total flavonoid content, TPC—Total phenolic content, TRACP—tartrate-resistant acid phosphatase; SO—soy oil, STZ—streptozotocin; VD3—1,2-dyhydroxyvitamin D3; QE—quercetin equivalents, WSBP—water-solubilized bee pollen extract, ↑—High; ↓—Low.
Figure 2Rhamnogalacturonan type I (RG-I) (a) and type II (RG-II) (b), homogalacturonan (HG) (c) and arabinogalactan (AG) (d) structures. *—the compounds can bind to rhamnose, galactose, arabinose [29].
In vitro summary of the main studies regarding the effect of BP and BB on multiple cancer and non-cancer cell lines.
| BP or BB | Cell Lines | Treatment Schemes | Obtained Results | References |
|---|---|---|---|---|
| Cernitin T-60 (water-soluble pollen extract with > 90% pollen | Human prostate cell line DU-145 | The inhibitory patterns for both the naturally occurring fraction designated as FV-7 in the water soluble component of the pollen extract Cernilton® and an authentic synthetic sample of DIBOA were tested at 1, 10 and 100 g/ml | ↓ Growth inhibition (1 μg/mL) of V-7 or DIBOA for day 1–6.; | [ |
| Chloroform extract from | Human cancer cell lines (PC-3, lncap, MCF-7, Hela, BEL-7402, BCG-823, KB, A549 and HO8910) | Cell lines treated with various concentrations of CPBC (12.5–100 μg/mL) for 24 h | CPBC remarkably induced concentration-dependent cytotoxicity in PC-3 and lncap cells; 100 μg/mL CPBC could induce cytotoxicity in MCF-7, Hela, BEL7402, BCG-823, KB, A549 and HO8910 cells | [ |
| Extracted and fractionated BP polysaccharides from | Human colon cancer HT-29 and HCT116 cells | Cells treated with varying concentrations (0, 0.5, 2, 5 mg/mL) of various BP polysaccharides for 72 h | Fractions and sub-fractions of WRPP showed a concentration-dependent proliferation-inhibitory effect on HT-29 and HCT116 cells | [ |
| BB ethanolic extracts (ebbs) obtained from three different samples of BB from Poland | Glioblastoma cell line (U87MG) | BB extract—effects of EBB1, EBB2, EBB3 (10, 20, 30, 50, 100 µg/mL) on the viability of glioblastoma cell line (U87MG) were studied after 24 h, 48 h and 72 h of treatment. | time-dependent inhibitory effect on the viability of U87MG cells treated EBB; | [ |
| DASC, U87MG, svgp12 | Cytotoxic effect using MTT assay: EBB (50 mg/mL), combination with TMZ (20 mm) on cells after 24 h, 48 h and 72 h of the treatment | ↓ Cell viability: EBB = 62.4 ± 4.6% on U87MG after 72 h; | [ | |
| Date palm pollen (DPP) and volatile esters of fermented and non-fermented | MCF-7 cell line | Antioxidant activities were determined using DPPH assay, the ferric reducing antioxidant power assay and ABTS assay. Anti-breast-cancer and antiviral activities were determined using the MTT assay | ↑ Antioxidant activity of the FDPP extract of 3.16, 3.42, and 2.14 times that of the DPP extract as determined by the ABTS, ferric reducing antioxidant power (FRAP) and DPPH assays; | [ |
| BPE (bee pollen extract) | MCF-7 and L929 cell lines | Antioxidant activities determined with DPPH assay. | BPE EC50: 0.5 mg/mL; | [ |
| Dimethyl sulfoxide (DMSO) extracts of BP | HL-60 Myeloid Cancer Cell Lines | DMSO extracts of BP were incubated separately with HL-60 cells, and caspase-3 activity evaluated | ↑ Apoptosis DMSO extract of pollen (2 mg/mL): 52.2%; | [ |
| Six BB samples (BB1-BB5, BBC) | Human tumor cell lines: MCF-7, NCI-H460, Hela, HepG2; | In vitro assays—cytotoxicity (ranging from > 400 to 68 µg/mL) on all cell lines | BB1 GI25: 164 µg/mL on MCF-7; 345 µg/mL on Hela; | [ |
Note: A549—lung carcinoma cell lines; BCG-823—gastric adenocarcinoma cells; BEL7402—human liver cancer cell line; CP—cisplatin; DASC—diffuse astrocytoma; DIBOA—hydroxamic acid, 2,4-dihydroxy-1,4-benzoxazin-3-one; DU-145—human prostate cancer cell line; HCT116—human colon cancer cell line; HeLa—human cervix carcinoma cell lines; HepG2—liver hepatocellular carcinoma; HL-60—human leukemia cell line; HO8910—ovarian carcinoma cell lines; HT-29—human colon adenocarcinoma cell line; KB—squamous carcinoma cells; L929—mouse fibroblastic cell line; LNCaP—human prostate adenocarcinoma cells; MCF-7—human breast cancer cell line; MTT—3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NCI-H460—human lung cancer cell line; PLP2—Non-Tumor Porcine Liver Cells; SVGp12—normal human astroglia; TMZ—temozolomide; U87MG—human glioblastoma cell lines; ↑—increase; ↓—decrease.
In vivo studies regarding the effect of BP in multiple diseases which imply liver damage.
| Animal Models | The Type of BP, Collection Site and Application Method | Applied Treatment | Effects of BP Administration | References |
|---|---|---|---|---|
| Eighty male Wistar rats weighing 180–240 g were divided into eight equal groups | Cernitin T60 and Cernitin GBX of specially selected plants, Sweden, orally administered | G1—control; | ↑ liver cells apoptosis in G2 | [ |
| Forty male mongrel rabbits with initial body weight 3.0–3.8 kg fed with a standard basic diet, randomly divided into four equal groups | Cernitin T60 and Cernitin GBX—from six plant species: Rye grass, Maize, Timothy grass, Pine, Alder flower and Orchard grass; orally administered | G1—control, G2—HFD, G3– HFD + pollen extracts (Cernitin T60—50 mg/kg/24 h + Cernitin GBX—10 mg/kg/24 h) orally, G4—HFD + clofibrate (Pharmaceutical Works ‘Polfa’/25 mg/kg/24 h) orally. HFD = (g/kg/24 h) cholesterol (0.5), hydrogenated coconut oil (l.0), cholic acid (0.1). The experiment lasted 12 weeks | The intima of the aorta of rabbits of G1 (controls) was unchanged. | [ |
| S180-bearing mice | G1—normal saline injections. | ↓ growth of S180 (51.26% inhibition rate) with RPP | [ | |
| Eighty male CF1 mice (19–21 g) divided into 8 groups | Bee pollen from mesquite ( | G1—provided with cooking oil, G2—200 mL of mesquite BP extract; G3—200 mL of extract of mesquite BP; G4—200 mL of vitamin E (400 UI); G5 intoxicated with bromobenzene—200 mL, 94.211 mg/mL in cooking oil; G6-8 intoxicated with bromobenzene—200 mL, 94.211 mg/mL in cooking oil after the administration of vitamin E (400 UI) | ↑ antioxidant activity in vivo on the liver of bromobenzene-intoxicated mice; | [ |
| Female CBA/Hr mice aged 4 months. Experimental and control group consisted of 10 mice each | Mice were fed 14 days before testing either with commercial food pellets (control group) or with commercial food pellets mixed with bee pollen (100 mg/kg bw) | ↓ TBARS in the liver, but without effect in brain; | [ | |
| Male Kunming mice divided into five groups of 12 animals each | In vivo study: SCPE (10, 20 and 40 g/kg) administered to CCl4-induced acute liver damage in mice | SCPE—total phenolic content (53.74 ± 1.21 mg GAE/g), total flavonoid content (38.29 ± 0.91 mg Rutin/g); | [ | |
| Forty-nine 12 weeks old Sprague-Dawley rats divided in seven groups | BP collected during flowering season in Turkey (Western Black Sea region) with dominant component | G1—control, 0.9% NaCl (i.p.); G2—control, 0.8 mL/kg olive oil (i.p.); G3—control, 0.8 mL/kg Ethanol (i.p.); G4—CCI4, 0.8 mL/kg CCI4 in olive oil; G5—Silibinin, 0.8 mL/kg CCI4 in olive oil + Silibinin (50 mg/kg/day) gavage; G6—low pollen, 0,8 mL/kg CCI4 in olive oil (i.p.) + Pollen (200 mg/kg/day) gavage; G7—high pollen, 0,8 mL/kg CCI4 in olive oil (i.p.) + Pollen (400 mg/kg/day) gavage | ↑ AI in G4 compared to G5–G7. | [ |
| Male albino mice divided in: six groups with 11 animals each. | Effects of water extracts of Egyptian bee pollen (WEBP) from Beni-Suef, Upper Egypt, on cisplatin (CDDP) induced hepatic, renal, testicular and genotoxicity in male albino mice; | G1—negative control (0.9% NaCl solution by intraperitoneal injection (i.p.) twice/week for 3 weeks). | The treatment of mice with WEBP at a dose of 140 mg/kg b. wt./day, for 14 days with CDDP (2.8 mg/kg b. wt.) resulted in: | [ |
| 36 adult male Sprague Dawley rats divided into six groups of six animals each | G1—normal saline (10 mL/kg/day) for 12 days and i.p. with saline (10 mL/kg) at the 7th day | ↓ MDA in kidney and dose-dependent in liver | [ |
Note: AI—apoptosis index; ALT—alanine aminotransferase; AOE—modulated antioxidant enzymes; AST—aspartate aminotransferase; CAT—catalase; CCl4—Carbon tetrachloride; CDDP—cis-diamminedichloroplatinum(II), cipslatin; Cy—cyclophosphamide; GAE—gallic acid equivalent; GBX—fat-soluble (10–16% of phytosterols) substances; GSH—reduced glutathione; GSH-Px—glutathione peroxidase; HFD—high-fat diet; iNOS—inducible nitric oxide synthase; LPO—lipid peroxides; MDA—malondialdehyde; RBC—red blood cell; SOD—superoxide dismutase; TBARS—thiobarbituric acid reactive substances;; WSDP—water-soluble propolis derivative; ↓—decrease; ↑—increase.
Enzyme-level changes induced by BB in response to anti-cancer therapies.
| Molecules | Organs | Species | Agents | Change | References |
|---|---|---|---|---|---|
|
| |||||
| CAT | Liver, brain, heart | rats | Propoxur | ↑ | [ |
| kidney | rats | Propoxur | ↓ | [ | |
| Testis | rats | CdCl2 | ↑ | [ | |
| Plasma | rats | CCl4 | ↓ | [ | |
| Liver | rats | CCl4 | ↓ | [ | |
| Liver, kidney, testis | mice | Cisplatin | ↑ | [ | |
| Liver, kidney | rats | Cisplatin | ↑ | [ | |
| GST | Liver, kidney, testis | mice | Cisplatin | ↑ | [ |
| GSH | Liver, kidney | rats | Cisplatin | ↑ | [ |
| Testis, prostate | rats | CdCl2 | ↑ | [ | |
| Brain | rats | F | ↑ | [ | |
| SOD | Liver, kidney, heart, brain | rats | Propoxur | ↑ | [ |
| Testis | rats | CdCl2 | ↑ | [ | |
| Liver | mice | CCl4 | ↑ | [ | |
| Liver | rats | CCl4 | ↑ | [ | |
| Liver | rats | CCl4 | ↓ | [ | |
| Plasma | rats | CCl4 | ↑ | [ | |
| Liver, kidney | rats | Cisplatin | ↑ | [ | |
| GSH-Px | Liver, kidney, heart, brain | rats | Propoxur | ↑ | [ |
| Liver | mice | CCl4 | ↑ | [ | |
| MDA | Liver | mice | Bromobenzene | ↓ | [ |
| Brain | rats | F | ↓ | [ | |
| Liver, kidney | rats | Cisplatin | ↓ | [ | |
| Liver, kidney, testis | mice | Cisplatin | ↓ | [ | |
| Liver | mice | CCl4 | ↓ | [ | |
| Liver | rats | CCl4 | ↓ | [ | |
| Liver | rats | CCl4 | ↓ | [ | |
| Liver, kidney, heart, brain | rats | Propoxur | ↓ | [ | |
| iNOS | Liver, kidney | rats | Cisplatin | ↓ | [ |
|
| |||||
| IL-6 | Prostate, testis | rats | β-estradiol | ↓ | [ |
| TNF-α | Prostate, testis | rats | β-estradiol | ↓ | [ |
Note: CAT—catalase; CCl4—carbon tetrachloride; CdCl2—cadmium chloride; F—fluoride; GSH—reduced glutathione; GSH-Px—glutathione peroxidase; GST—glutathione peroxidase; iNOS—inducible nitric oxide synthase; IL-6—interleukin-6; MDA—malondialdehyde; Propoxur—2-isopropoxyphenyl methylcarbamate; TNF-α—tumor necrosis factor-alpha; ↑—Increased molecular change by chemotherapeutic agents; ↓—Decreased molecular change by chemotherapeutic agents.
Effects of BP extract treatmens in patients with chronic prostatitis or chronic pelvic pain syndrome.
| BP | Patient Disorders | Treatment Schemes | Obtained Results | References |
|---|---|---|---|---|
| BP extract Cernilton® (several different plants from Sweden) | 15 patients with chronic relapsing non-bacterial prostatitis or prostatodynia | Cernilton® administration varied from 1 to 18 months | ↑ lasting relief and symptom-free in seven patients | [ |
| BP extract Cernilton® (several different plants in southern Sweden) | 53 patients with benign prostatic hyperplasia (BPH) entered in a double-blind placebo-controlled study | Patients were administered Cernilton® ( | ↑ subjective improvement with Cernilton® (69%) compared with placebo (30%) | [ |
| BP extract Cernilton® R N | treatment of chronic prostatitis syndrome in 90 patients; G1—those without associated complicating factors (CFs) ( | Cernilton® R N given in a dose of 1 tablet tid and in most cases treatment was continued for 6 months | ↑ response in the group without CFs, 56 (78%); 26 (36%) were cured of their symptoms and signs | [ |
| BP extract EA-10, P5 (375 mg/pill) | G1—68 cases of CP | G1: group A ( | Pre-treatment group: | [ |
| Cernilton®/Cernitin pollen extract | 87 patients: | Patients received two capsule daily from 4 to 6 weeks | ↑ pain/discomfort domain score | [ |
| Prostat/Poltit | 115 patients with chronic nonbacterial prostatitis | Each patient was given 1 tablet of prostat (70 mg P5 + 4 mg EA10) twice a day for 8 weeks | ↓ NIH-CPSI and QoL | [ |
| Prostat/Poltit (74 mg highly defined extract of BP from selected | Two groups: 58 patients between 20 and 55 years old with chronic nonbacterial prostatitis or chronic pelvic pain syndrome were randomized to receive Prostat/Poltit ( | The dose was three tablets/day. The placebo tablets were identical in appearance to the active tablets, but contained no pollen extract. | patients taking Prostat/Poltit: | [ |
| BP extract Cernilton® | 139 men randomly allocated to the pollen extract ( | Participants were randomised to receive oral capsules of the pollen extract (2 capsules q8 h) or placebo for 12 wk | ↑ individual domains pain, QoL and NIH-CPSI score after 12 wk of treatment with pollen extract compared to placebo. | [ |
| DEPROX 500® (1 g pollen extract (500 mg per tablet) and vitamins | 87 males (25 class IIIa and 62 class IIIb) with a mean age of 33.6 ± 5.9 years with chronic prostatitis/chronic pelvic pain syndrome | Participants were randomised to receive oral capsules of DEPROX 500® (two capsules/day; | ↓ NIH-CPSI total score by ≥ 25% | [ |
Note: BPH—Benign Prostatic Hyperplasia; LEPS—leukocytes in expressed prostatic secretion; MDA—malondialdehyde; NIH-CPSI—The National Institutes of Health Chronic Prostatitis Symptom Index; NIH—National Institutes of Health; NO—nitric oxide; QoL—Quality of Well-Being; SOD—superoxide dismutase; WBC—white blood cell count; ↓—decrease; ↑—increase.